
Mark Ey, RPh, details the patient-focused factors of the ACCESS to Pharmacy Care Program and the ways in which valued care translates to reimbursement.

Mark Ey, RPh, details the patient-focused factors of the ACCESS to Pharmacy Care Program and the ways in which valued care translates to reimbursement.

Mark Ey, RPh, from NCPA, joins to discuss the opportunities for independent pharmacies within the ACCESS to Pharmacy Care Program.

Researchers say this net loss is unlikely to reverse without state and federal policy changes, including PBM reform.

Among a collection of patients across 15 pharmacies, researchers assessed acceptability and satisfaction with pharmacist-led clinical services.

Zaid Fadul, MD, FS, FAAFP, joins for part 2 to discuss what greater adoption of AI across health care ecosystems might mean for pharmacists, patients, and more.

For pharmacies competing with CVS and relying on Caremark to serve patients, the prospect of those businesses operating under separate ownership is significant.

The inquiry puts audit practices, including how pharmacies are selected for audit, proportionality, and pharmacy advocacy in focus.

The finalized rule is another step in the right direction for pharmacies calling for reform due to underwater reimbursement and other PBM pressures.

Allison Schneider, MPH, provides a detailed update regarding pharmacies’ impact within Medicare price negotiations and the legislation further impacting businesses.

This episode breaks down how PBMs conduct inventory audits, the sourcing and timing issues that trigger recoupments, and how pharmacies can prepare and push back.

In part 2, Allison Schneider, MPH, discusses PBM and 340B reform that could compound pharmacies’ burden amid ongoing Medicare drug price negotiations.

Allison Schneider, MPH, provides expertise on how IRA drug price negotiations have impacted pharmacies in 2026 and what’s to come in the years ahead.

AJ Barbarito, Esq, explains how ERISA and Medicare Part D preemption limit state PBM laws and why a private right of action may be the most effective path forward.

Lara Zakaria, PharmD, MS, CNS, FMCP, illustrates the breadth of health technology going in and out of community pharmacy practice.

Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.

AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.

In celebration of American Pharmacists Month, Melissa McGivney, PharmD, FAPhA, FCCP, provides a snapshot of where the profession has come and where it still has to go.

Independent pharmacies adapt to specialty drugs, biosimilars, cold-chain, and REMS demands.

During American Pharmacists Month, pharmacy teams reflect on their roles and explore ways to enhance patient care.

In celebration of the organization’s recent convention, NCPA released its annual digest report for members, providing a detailed overview of independent community pharmacy.

In part 2 of our pre-election series, detailing key health policies for pharmacists at this year’s midterms, a legal expert touches on MFN pricing, ACA subsidies, and more.

This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.

As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.

Chad Worz, PharmD, BCGP, FASCP, explains why the Main Street Pharmacy Access Act's reimbursement provisions are key to unlocking pharmacy's clinical future.

Observed by APhA and ASHP since 2023, bipartisan support has garnered to give pharmacy workforce suicide awareness its own federally recognized day.

Chad Worz, PharmD, BCGP, FASCP, discusses the Main Street Pharmacy Access Act, a revolutionary pharmacy-focused bill moving through Congress.